20.
INCOME TAXES:

During the year ended December 31, 2025, the Company adopted ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The standard enhances the annual income tax disclosures to address investor requests for more information about the tax risks and opportunities present in an entity's worldwide operations.

The components of income before income taxes are as follows (in thousands):

 

 

 

Year ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

United States

 

$

95,422

 

 

$

72,823

 

 

$

71,514

 

Foreign

 

 

199,374

 

 

 

199,305

 

 

 

173,657

 

Income before income taxes

 

$

294,796

 

 

$

272,128

 

 

$

245,171

 

 

The components of income tax expense are as follows (in thousands):

 

 

 

Year ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Current income tax expense:

 

 

 

 

 

 

 

 

 

U.S. Federal

 

$

19,230

 

 

$

34,199

 

 

$

15,848

 

U.S. State

 

 

1,965

 

 

 

3,452

 

 

 

3,048

 

Foreign

 

 

32,562

 

 

 

31,515

 

 

 

27,030

 

 

 

 

53,757

 

 

 

69,166

 

 

 

45,926

 

Deferred income tax benefit:

 

 

 

 

 

 

 

 

 

U.S. Federal

 

 

(388

)

 

 

(16,799

)

 

 

460

 

U.S. State

 

 

179

 

 

 

(2,995

)

 

 

(3,936

)

Foreign

 

 

(827

)

 

 

677

 

 

 

(290

)

 

 

 

(1,036

)

 

 

(19,117

)

 

 

(3,766

)

Total income tax expense:

 

 

 

 

 

 

 

 

 

U.S. Federal

 

 

18,842

 

 

 

17,400

 

 

 

16,308

 

U.S. State

 

 

2,144

 

 

 

457

 

 

 

(888

)

Foreign

 

 

31,735

 

 

 

32,192

 

 

 

26,740

 

Total income tax expense

 

$

52,721

 

 

$

50,049

 

 

$

42,160

 

 

A reconciliation of the U.S. federal statutory income tax rate to the Company's effective tax rate is as follows (in thousands, except percentages):

 

 

 

Year-ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

 

 

Amount

 

 

Percent

 

 

Amount

 

 

Percent

 

 

Amount

 

 

Percent

 

U.S. tax effects:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Federal statutory income tax rate

 

$

61,907

 

 

 

21.0

%

 

$

57,147

 

 

 

21.0

%

 

$

51,486

 

 

 

21.0

%

Domestic federal

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

R&D credits

 

 

(4,295

)

 

 

-1.5

%

 

 

(7,842

)

 

 

-2.8

%

 

 

(6,239

)

 

 

-2.5

%

Nontaxable and nondeductible items:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Executive compensation disallowed under §162(m)

 

 

4,348

 

 

 

1.5

%

 

 

4,193

 

 

 

1.5

%

 

 

4,072

 

 

 

1.7

%

Other

 

 

887

 

 

 

0.3

%

 

 

331

 

 

 

0.1

%

 

 

147

 

 

 

0.1

%

Federal effect of cross-border tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Global intangible low-taxed income

 

 

1,894

 

 

 

0.6

%

 

 

5,429

 

 

 

2.0

%

 

 

3,861

 

 

 

1.6

%

Subpart F income

 

 

462

 

 

 

0.2

%

 

 

2,835

 

 

 

1.0

%

 

 

(746

)

 

 

-0.3

%

Other

 

 

(89

)

 

 

0.0

%

 

 

(406

)

 

 

-0.1

%

 

 

(245

)

 

 

-0.1

%

Federal reconciling items

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

(3,644

)

 

 

-1.2

%

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

215

 

 

 

0.1

%

 

 

(1,241

)

 

 

-0.5

%

 

 

410

 

 

 

0.2

%

Changes in federal valuation allowances

 

 

(720

)

 

 

-0.2

%

 

 

(67

)

 

 

-0.1

%

 

 

(157

)

 

 

-0.1

%

Domestic state and local income taxes, net of federal effect

 

 

1,786

 

 

 

0.6

%

 

 

322

 

 

 

0.1

%

 

 

(702

)

 

 

-0.3

%

Foreign tax effects:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ireland

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Statutory income tax rate differential

 

 

(16,964

)

 

 

-5.8

%

 

 

(16,580

)

 

 

-6.0

%

 

 

(13,525

)

 

 

-5.5

%

Foreign tax credits

 

 

(3,604

)

 

 

-1.2

%

 

 

(2,964

)

 

 

-1.1

%

 

 

(2,104

)

 

 

-0.9

%

Other

 

 

(431

)

 

 

-0.2

%

 

 

167

 

 

 

0.1

%

 

 

(105

)

 

 

0.0

%

China

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Withholding tax on license fees and royalties

 

 

10,587

 

 

 

3.6

%

 

 

9,225

 

 

 

3.4

%

 

 

6,185

 

 

 

2.5

%

Other

 

 

(27

)

 

 

0.0

%

 

 

(24

)

 

 

0.0

%

 

 

(33

)

 

 

0.0

%

Other foreign jurisdictions

 

 

409

 

 

 

0.1

%

 

 

(476

)

 

 

-0.2

%

 

 

(145

)

 

 

-0.1

%

Total

 

$

52,721

 

 

 

17.9

%

 

$

50,049

 

 

 

18.4

%

 

$

42,160

 

 

 

17.2

%

 

As of December 31, 2025 and 2024 the Company had $57.0 million and $40.7 million, respectively, of taxes receivable included in other current assets on the Consolidated Balance Sheets. In January 2026, the Company received $39.0 million of the taxes receivable from the United States Treasury.

 

 

 

 

The following table summarizes the Company's cash paid for income taxes, net of refunds received by jurisdiction (in thousands):

 

 

 

December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

United States:

 

 

 

 

 

 

 

 

 

Federal

 

$

33,507

 

 

$

45,527

 

 

$

57,263

 

State

 

 

2,629

 

 

 

2,545

 

 

 

2,523

 

Total United States

 

 

36,136

 

 

 

48,072

 

 

 

59,786

 

Foreign:

 

 

 

 

 

 

 

 

 

Ireland

 

 

24,127

 

 

 

13,174

 

 

 

28,110

 

China

 

 

10,783

 

 

 

9,236

 

 

 

6,161

 

Other foreign jurisdictions

 

 

392

 

 

 

1,491

 

 

 

2,119

 

Total foreign

 

 

35,302

 

 

 

23,901

 

 

 

36,390

 

Total cash taxes paid

 

$

71,438

 

 

$

71,973

 

 

$

96,176

 

 

 

The following table summarizes the Company's tax credit carry forwards for tax return purposes as of December 31, 2025 (in thousands):

 

 

 

Tax Benefit

 

 

Expiration Date

Tax credit carry forwards:

 

 

 

 

 

U.S. State research tax credits

 

$

9,628

 

 

2036-2040

Total credit carry forwards

 

$

9,628

 

 

 

 

Significant components of the Company's net deferred tax assets and liabilities are as follows (in thousands):

 

 

 

December 31,

 

 

 

2025

 

 

2024

 

Deferred tax asset:

 

 

 

 

 

 

Capitalized research expenditures

 

$

54,931

 

 

$

55,277

 

Retirement plan

 

 

14,185

 

 

 

13,633

 

Tax credit carry forwards

 

 

9,628

 

 

 

9,542

 

Accruals and reserves

 

 

7,100

 

 

 

6,988

 

Lease liabilities

 

 

5,874

 

 

 

6,073

 

Stock-based compensation

 

 

1,701

 

 

 

1,475

 

Deferred revenue

 

 

588

 

 

 

655

 

Other

 

 

3,706

 

 

 

2,783

 

 

 

 

97,713

 

 

 

96,426

 

Valuation allowance

 

 

(9,159

)

 

 

(10,167

)

Deferred tax assets

 

 

88,554

 

 

 

86,259

 

Deferred tax liability:

 

 

 

 

 

 

Lease assets

 

 

(4,891

)

 

 

(5,297

)

Acquisition goodwill

 

 

(2,088

)

 

 

(1,854

)

Other

 

 

(2,121

)

 

 

(788

)

Deferred tax liabilities

 

 

(9,100

)

 

 

(7,939

)

Net deferred tax assets

 

$

79,454

 

 

$

78,320

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent on the Company's ability to generate future taxable income to obtain benefit from the reversal of temporary differences, net operating loss carryforwards and tax credits. As part of its assessment, management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. During the year ended December 31, 2025, based on our previous earnings history, a current evaluation of expected future taxable income and other evidence, we determined to retain the valuation allowance that relates to New Jersey research and development credits. As of December 31, 2025, there is not sufficient evidence to release the valuation allowance that has been recorded for New Jersey research and development credits. Additionally, the Company recognized a gain on available-for-sale securities during the year that, if sold, would offset the capital loss, and, as a result, the valuation allowance on the capital loss was reversed. There are no indicators against the realizability of the remaining net deferred tax asset.

On December 27, 2018, the Korean Supreme Court, citing prior cases, held that only royalties paid with respect to Korean registered patents are considered Korean source income and subject to Korean withholding tax under the applicable law and interpretation of the Korea-U.S. Tax Treaty. The Company has incurred Korean withholding tax of $14.9 million for each of the years ended December 31, 2018, through December 31, 2022. Based on the Korean Supreme Court decision, a tax refund request on behalf of the Company was filed with the Korean National Tax Service (KNTS) for the period from January 1, 2018, to December 31, 2022. The Company received a formal rejection from the KNTS; and in May 2022 filed an appeal with the Korean Tax Tribunal. On December 18, 2023, the Company received a formal rejection from the Tax Tribunal. Anticipating the rejection of the appeal, in September 2023 the Company filed a petition to the District Court.

On September 18, 2025, the Korean Supreme Court issued a decision, changing its long-standing position on the taxation of royalties for patents not registered in Korea. The court held that royalties paid for licensing of a patent constitute Korean source income if the patented technology is actually used in the territory of the Republic of Korea. Based on discussions with a prominent Korean law firm, the Company has been advised that there is still a more likely-than-not chance of success, as the manufacturing and sales process occurs within and without the Republic of Korea. During the latest court appearance in November 2025, the judge requested additional information from the Korean Tax Authority regarding what amount of royalties would be considered Korean use. The next court date is scheduled for March 2026.

As a result, the Company has recorded a long-term receivable of $53.8 million and $52.9 million as of December 31, 2025 and 2024, respectively, for the receipt of the Korean withholding tax. The Company also recorded foreign exchange gain of $935,000, foreign exchange loss of $7.2 million and foreign exchange loss of $732,000 for the years ended December 31, 2025, 2024 and 2023, respectively, due to the fluctuation of the Korean Won to the U.S. Dollar and resulting remeasurement of this Won-denominated receivable. The Company will amend U.S. federal tax returns for the 2018 to 2022 years when the anticipated refund from KNTS is received to offset the additional tax liability. The Company has recorded a long-term payable of $15.7 million as of December 31, 2025 and 2024, for the estimated amounts due to the U.S. federal government based on the amendment of the Company's U.S. tax returns, indicating that lower withholding amounts were required.

The Company is not subject to examinations by the federal tax authority for the years prior to 2022. The Company is presently undergoing a federal tax audit for the 2023 tax year and a state of California tax audit for the 2021 and 2022 tax years. Both audits are currently in the information-gathering phase.

The above estimates may change in the future and upon settlement.

Historical Timeline

Fiscal YearFiled
2025Feb 19, 2026Showing above
2024Feb 20, 2025
2023Feb 22, 2024
2022Feb 23, 2023
2021Feb 23, 2022
2020Feb 18, 2021
2019Feb 20, 2020
2018Feb 21, 2019
2017Feb 22, 2018
2016Feb 23, 2017
2015Feb 25, 2016

About Income Taxes Disclosures

The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.

Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.